Markets
Federal Reserve Soft Landing
Stick the
Landing
(Photo by ABC Photo Archives/Disney General Entertainment Content via Getty Images)

With the Fed about to cut, is the soft landing on track?

Only one tiny economic analyst has the guts to find out.

Did they pull it off? Or did they pull a fast one?

If the Federal Reserve cuts short-term interest rates next month, as Wall Street thinks is almost certain, it will mark an important milestone in the multi-year debate over whether the economy could experience a so-called soft landing.

The cognoscenti will remember that a recession — the “hard landing” scenario — was widely thought inevitable after the Fed began to jack up interest rates in 2022 to rein in post-pandemic inflation.

Others, including those in the Biden administration and the Federal Reserve, thought it just might be possible to slowly bring inflation back to earth, without crashing the economy. (A deep recession followed the last serious inflationary episode in the early 1980s.)

That magic combination — inflation coming down, without unemployment spiking — was the so-called soft-landing scenario, something few thought likely as the Fed delivered sharpest rise in interest rates since back in the early 1980s.

But, remarkably, with inflation down, the job market strong and the economy expanding, it looks like we may be on track to pulling it off.

But there’s only one purely scientific way to tell for sure.

In honor of the looming 50th anniversary of motorcycle daredevil Evel Knievel’s iconic attempt to ride a rocket-powered motorcycle over a gap in Idaho’s Snake River Canyon, we’ve uploaded key economic data series to Line Rider, the hypnotic old-school browser game.

The main character, a scarfed sled rider by the name of Bosh, is notoriously sensitive to sudden shifts in the trajectory of the lines he follows. In fact, so sensitive was Bosh to the actual numbers, that we were forced to do 1-year moving averages to give him some terrain he could actually traverse.

Even so, you’ll notice that for the most part Bosh’s ride over the last few years of American economic data, is a remarkably smooth downhill cruise that seems soft landing-y.

On the inflation front, the Consumer Price Index — which hit 9.1% June 2022 — has come more or less steadily dow to 2.9%. That looks pretty soft.

Consumer Price Index

The job market, too, seems to have pulled off a return to earth. The jobless rate is up from 3.6% in June 2022 to 4.3% in July, which, while an unfriendly trend, is still well below the average of roughly 6% during the two decades preceding Covid. Initial claims for unemployment insurance — another closely watched job market metric — have also normalized from highly elevated Covid-era levels.

Unemployment Insurance Initial Claims

And the economy as a whole, as measured by GDP, has considerable pep at the moment, expanding at a healthy 3% annualized pace in the second quarter.

But you’ll notice, Bosh has a bit of trouble negotiating a pretty sharp slowdown that hit back in 2022.

Bosh might be onto something here. That divot reflects in part the fact that GDP actually did drop for two straight quarters in early 2022, which is often thought of as an unofficial definition for a recession. 

Gross Domestic Product

Nobody called it a recession at the time, largely because this negative lurch was driven by big swings in trade and inventories, while private sector demand was positive over this period. This was a time of normalization from super strong growth the economy generated in 2021, and all the while, the unemployment stayed remarkably low. 

Also, the National Bureau of Economic Research — which has taken on the role of official decider of what qualifies for R-word status — never declared that it was one. 

Still, at least by the super-sensitive standards of Line Rider, this landing might not have been quite as soft as it appears to us all now.

More Markets

See all Markets
markets

Intuit, Workday jump amid Iran war fueling flight-to-software trade

Cash flow-positive software companies — the same ones that were seen as doomed to obsolescence by AI a few weeks back — jumped Thursday, with Oracle, Workday, Intuit, and Salesforce staying above water despite the general downtrend in the big indexes.

Some of the uptick is likely linked to the better-than-expected weekly jobless claims numbers that came in early today, which eased concerns about a recession brought on by the most recent monthly employment report. (Payroll-processing stocks like Paycom Software, Paychex, and Automatic Data Processing are clearly breathing a sign of relief.)

And given that these software companies often have a “seat-based” revenue model, the fact that human butts are not rapidly being replaced by AI-enhanced robot keisters gives them a lift as well.

Also as we’ve said before, amid the chaos and uncertainty of the Iran war, the steady cash flows and predictable short-term outlook of software-as-a-service stocks have a definite appeal.

Even if you think that over the long term AI will end up slaughtering these cash cows, that’s a problem for a day perhaps three to five years in the future, whereas the Iran war is a growing risk investors increasingly can’t ignore today.

markets

Rocket Lab slips with other momentum stocks despite DOD hypersonic test deal, new analyst “buy” call

Rocket Lab slipped early Thursday along with other momentum stocks, despite announcing a new $190 million deal for 20 tests of hypersonic rockets for the Department of Defense and picking up a new bullish analyst call.

The commercial space launch company called the deal to launch 20 hypersonic test flights over a four-year period in collaboration with Kratos Defense its “single largest launch agreement yet.”

Separately, analysts at brokerage firm Clear Street initiated coverage of Rocket Lab with a “buy” rating and an $88 price target — essentially the same as Wall Street’s $88.38 consensus, according to FactSet. That implies upside of about 27% for the stock compared to yesterday’s close. Clear Street analysts wrote:

“Despite shares rising 289% (vs. 26% for the NASDAQ) over the past year, we see further upside. Our $88 target is based on 20x 2030E EV/Sales, in line with the ~30x NTM EV/Revenue average over the past year when discounted to present value. We anchor on 2030E to capture the payoff from ~16 annual Neutron launches following a multi-year investment cycle. Our outlook incorporates estimated dilution and proceeds from the $1B equity distribution agreement announced on 3/17/2026.”

The favorable headlines for Rocket Lab weren’t enough to help the shares overcome a general downdraft for high-beta momentum stocks such as itself. They are getting hammered early on the deteriorating situation in the Mideast war.

Separately, analysts at brokerage firm Clear Street initiated coverage of Rocket Lab with a “buy” rating and an $88 price target — essentially the same as Wall Street’s $88.38 consensus, according to FactSet. That implies upside of about 27% for the stock compared to yesterday’s close. Clear Street analysts wrote:

“Despite shares rising 289% (vs. 26% for the NASDAQ) over the past year, we see further upside. Our $88 target is based on 20x 2030E EV/Sales, in line with the ~30x NTM EV/Revenue average over the past year when discounted to present value. We anchor on 2030E to capture the payoff from ~16 annual Neutron launches following a multi-year investment cycle. Our outlook incorporates estimated dilution and proceeds from the $1B equity distribution agreement announced on 3/17/2026.”

The favorable headlines for Rocket Lab weren’t enough to help the shares overcome a general downdraft for high-beta momentum stocks such as itself. They are getting hammered early on the deteriorating situation in the Mideast war.

markets

Uber will invest $1.25 billion in Rivian in a new robotaxi deal

EV maker Rivian surged more than 9% in premarket trading on Thursday following an announcement that Uber will invest up to $1.25 billion in the company through 2031 as part of a robotaxi partnership.

The deal will begin with an initial $300 million investment, and Uber will purchase 10,000 autonomous versions of the R2. Uber will have the option to buy 40,000 more in 2030.

The R2 is Rivian’s smaller, less expensive model and is set to roll out to buyers in the second quarter of this year.

Per a company filing on Thursday, Rivian “no longer expects to be adjusted EBITDA positive in 2027 due to an expected increase in R&D spend associated with the acceleration of its autonomy roadmap.”

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its Autonomy and AI Day in December.

The R2 is Rivian’s smaller, less expensive model and is set to roll out to buyers in the second quarter of this year.

Per a company filing on Thursday, Rivian “no longer expects to be adjusted EBITDA positive in 2027 due to an expected increase in R&D spend associated with the acceleration of its autonomy roadmap.”

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its Autonomy and AI Day in December.

markets

Lilly reports encouraging trial results for its next-gen GLP-1 shot

Eli Lilly released late-stage trial results for its next-generation GLP-1 shot, retatrutide, showing the drug helped patients lose more weight than anything currently on the market.

Patients taking the highest dose of retatrutide, 12 milligrams, lost 16.8% of their body weight after 40 weeks, more than its current bestseller, tirzepatide. The results also showed significant reduction in blood sugar levels.

The stock was flat in premarket trading following the news.

Lillys tirzepatide, sold under the brand names Zepbound and Mounjaro, is currently the most sold drug in the world. The companys sales have now outpaced its top rival, Novo Nordisk, which was the first to bring a GLP-1 to market but has seen sales decelerate as competitors have muscled in.

Still, some expect Lillys winning streak may not last forever. Analysts at HSBC gave the stock a rare downgrade earlier this week, citing a crowded market, among other factors.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.